Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Merck & Co. Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Loans payable and current portion of long-term debt	2,649)	1,372)	1,946)	2,412)	6,431)
Trade accounts payable	4,079)	3,922)	4,264)	4,609)	4,594)
Accrued and other current liabilities	15,694)	15,766)	14,159)	13,859)	13,053)
Income taxes payable	3,914)	2,649)	1,986)	1,224)	1,575)
Dividends payable	2,084)	1,985)	1,884)	1,768)	1,674)
Current liabilities	28,420)	25,694)	24,239)	23,872)	27,327)
Long-term debt, excluding current portion	34,462)	33,683)	28,745)	30,690)	25,360)
Deferred income taxes	1,387)	871)	1,795)	3,441)	1,015)
Other noncurrent liabilities	6,465)	8,792)	8,323)	9,434)	12,482)
Noncurrent liabilities	42,314)	43,346)	38,863)	43,565)	38,857)
Total liabilities	70,734)	69,040)	63,102)	67,437)	66,184)
Common stock, $0.50 par value	1,788)	1,788)	1,788)	1,788)	1,788)
Other paid-in capital	44,704)	44,509)	44,379)	44,238)	39,588)
Retained earnings	63,069)	53,895)	61,081)	53,696)	47,362)
Accumulated other comprehensive loss	(4,945)	(5,161)	(4,768)	(4,429)	(6,634)
Treasury stock, at cost	(58,303)	(57,450)	(56,489)	(57,109)	(56,787)
Total Merck & Co., Inc. stockholders’ equity	46,313)	37,581)	45,991)	38,184)	25,317)
Noncontrolling interests	59)	54)	67)	73)	87)
Total equity	46,372)	37,635)	46,058)	38,257)	25,404)
Total liabilities and equity	117,106)	106,675)	109,160)	105,694)	91,588)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Merck & Co. Inc. current liabilities increased from 2022 to 2023 and from 2023 to 2024.
Noncurrent liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Merck & Co. Inc. noncurrent liabilities increased from 2022 to 2023 but then slightly decreased from 2023 to 2024.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Merck & Co. Inc. total liabilities increased from 2022 to 2023 and from 2023 to 2024.
Total Merck & Co., Inc. stockholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Merck & Co. Inc. total Merck & Co., Inc. stockholders’ equity decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Merck & Co. Inc. (NYSE:MRK)

Balance Sheet: Liabilities and Stockholders’ Equity